pLenti-GPR155-sgRNA (GPR155基因敲除质粒)是一种在动物细胞中可以同时表达Cas9、目的基因的sgRNA和puromycin抗性基因的质粒。用于在动物细胞中直接基于CRISPR/Cas9技术敲除目的基因，或者通过包装慢病毒后基于CRISPR/Cas9技术敲除目的基因。本质粒中sgRNA的有效性已经通过T7EI法的验证。
本质粒在细菌中为Amp抗性，全长约13,000bp。本质粒的关键图谱信息请参考图1。本质粒可直接转染细胞用于目的基因的CRISPR/Cas9敲除，以及通过puromycin筛选稳定细胞株；也可以与pMDLg、Rev及VSV-g共转HEK293T细胞进行重组慢病毒(lentivirus)的包装，然后再用于感染细胞或组织并进行目的基因的CRISPR/Cas9敲除。
图1. 表达sgRNA、Cas9和puromycin抗性的pLenti-sgRNA质粒关键图谱信息。
本质粒中的sgRNA基于碧云天研发的CRISPR/Cas9 sgRNA快速筛选和验证体系获得，sgRNA的有效性已经通过T7EI法验证。
本质粒用于实验时，建议同时选购无任何靶向的对照质粒pLenti-Control-sgRNA (L00011)或靶向GFP的对照质粒pLenti-GFP-sgRNA (L00013)。
碧云天同时提供基于CRISPR/Cas9技术的GPR155基因敲除的质粒(L27195 pLenti-GPR155-sgRNA)、慢病毒(L27196 GPR155 Knockout Lentivirus)、HEK293T细胞(L27197 GPR155 Knockout HEK293T Cells)、HEK293T敲除细胞的RIPA裂解液(L27198 GPR155 Knockout HEK293T RIPA Lysate)、HEK293T敲除细胞的Trizol裂解液(L27199 GPR155 Knockout HEK293T Trizol Lysate)等产品，具体请在碧云天网站查询或在本产品网页点击相应产品。
GPR155基因的基本信息如下：
| Species | Gene Symbol | Gene ID | GenBank Accession | Transcript |
| Human | GPR155 | 151556 | BC035037 | NM_152529 |
| About the gene | |
| Official Symbol | GPR155 |
| Previous Symbol | - |
| Official Full Name | G protein-coupled receptor 155 |
| Synonyms | DEPDC3; DEP.7; FLJ31819; PGR22 |
| Location | 2q31.1 |
| Gene Type | protein_coding |
| Uniprot ID | Q7Z3F1 |
| Pathway/Library | others |
| Gene Summary | GPR155, which resides on chromosome 2q31.1, comprises eighteen exons and encodes a 97 kDa protein. GPR155 is a member of the seven-transmembrane domain of the GPCR family. Ligand binding activates the guanine nucleotide exchange factor activity of GPCRs that exchange GDP for GTP on its associated G protein. The Gα subunit bound to GTP dissociates from the Gβ and Gγ subunits to activate intracellular signaling proteins or target proteins directly. Limited information is available on the ligands for GPCRs at present. Huang XP, et al. detected some ligands for other GPCR families, GPR68 and GPR6514. GPCRs mediate diverse physiological processes such as the visual sensing, immune function, cell proliferation, and tumor metastasis15,16. It is therefore not surprising GPCRs represent 30–50% of the targets of currently marketed therapeutic drugs17,18,19,20. GPR155 is a unique member of GPCRs and there have been only a few reports on involvement in malignancies, such as follicular type papillary thyroid carcinoma and colorectal cancer21,22. In those earlier studies, GPR155 was listed in the results of microarray or proteomic analysis, and no data on the function and clinical significance of GPR155 was presented. GPR155 may be a biomarker that is useful for the diagnosis and prediction of hematogenous metastasis of patients with GC. |
| 产品编号 | 产品名称 | 包装 |
| L27195 | pLenti-GPR155-sgRNA | 5µg |
| — | 说明书 | 1份 |
-20℃保存，至少两年有效。
注意事项：碧云天拥有sgRNA序列的知识产权，如果需要sgRNA序列，请在订购后发送邮件向info@beyotime.com索取。sgRNA与质粒及其序列信息，未经碧云天书面许可不得用于任何商业用途，也不得移交给订货人所在实验室外的任何个人或单位。使用者在发表研究论文或结果时，应注明来源。
慢病毒包装使用的包装质粒，可以订购碧云天的Lentivirus Packaging Vectors Set A (L00002)，包括pMDLg、Rev和VSV-g。
对于非目录产品的CRISPR基因敲除用的sgRNA表达质粒的定制，可联系碧云天技术服务service@beyotime.com。
本产品仅限于专业人员的科学研究用，不得用于临床诊断或治疗，不得用于食品或药品，不得存放于普通住宅内。
为了您的安全和健康，请穿实验服并戴一次性手套操作。
